Pharmabiz

Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis

Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...
Pharmabiz

Vektor Medical receives US FDA 510(k) clearance for its next-generation vMap technology to enhance connectivity

Vektor Medical receives US FDA 510(k) clearance for its next-generation vMap technology to enhance connectivity: San Diego Saturday, December 13, 2025, 17:00 Hrs [IST] Vektor Medi ...
Pharmabiz

InnoCare Pharma’s next-generation TRK inhibitor zurletrectinib gets China NMPA approval to treat NTRK fusion-positive tumours

InnoCare Pharma’s next-generation TRK inhibitor zurletrectinib gets China NMPA approval to treat NTRK fusion-positive tumours: Beijing Saturday, December 13, 2025, 16:30 Hrs [IS ...
Pharmabiz

OTR Therapeutics and Zealand Pharma ink license agreement to develop novel therapeutics for metabolic diseases

OTR Therapeutics and Zealand Pharma ink license agreement to develop novel therapeutics for metabolic diseases: Shanghai Saturday, December 13, 2025, 16:00 Hrs [IST] OTR Therapeut ...